Outlook Therapeutics Inc (OTLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 32,024 | 47,229 | 10,357 | 23,392 | 33,709 |
| TOTAL | $45,618 | $57,786 | $20,389 | $30,979 | $43,018 |
| Non-Current Assets | |||||
| Investments And Advances | 708 | 766 | 797 | 794 | 802 |
| Other Non-Current Assets | 766 | 477 | 499 | 528 | 627 |
| TOTAL | $1,474 | $1,243 | $1,296 | $1,321 | $1,429 |
| Total Assets | $47,092 | $59,029 | $21,685 | $32,301 | $44,447 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 32,432 | N/A | 36,544 | 35,551 | 34,733 |
| Accounts payable and accrued liabilities | 5,553 | 4,363 | 3,480 | 6,575 | 5,055 |
| Accrued Expenses | 2,681 | 3,115 | 4,087 | 2,746 | 8,278 |
| TOTAL | $42,554 | $54,080 | $45,969 | $46,732 | $49,930 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 88,211 | 139,185 | 60 | 6 | 20 |
| TOTAL | $88,211 | $139,185 | $60 | $6 | $20 |
| Total Liabilities | $130,765 | $193,265 | $46,028 | $46,738 | $49,950 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 23,656 | 23,406 | 13,013 | 13,013 | 13,012 |
| Common Shares | 234 | 220 | 2,603 | 130 | 2,587 |
| Retained earnings | -548,976 | -593,385 | -479,096 | -467,918 | -454,927 |
| TOTAL | $-83,674 | $-134,236 | $-24,343 | $-14,438 | $-5,503 |
| Total Liabilities And Equity | $47,092 | $59,029 | $21,685 | $32,301 | $44,447 |